MA52012A - Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane - Google Patents

Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane

Info

Publication number
MA52012A
MA52012A MA052012A MA52012A MA52012A MA 52012 A MA52012 A MA 52012A MA 052012 A MA052012 A MA 052012A MA 52012 A MA52012 A MA 52012A MA 52012 A MA52012 A MA 52012A
Authority
MA
Morocco
Prior art keywords
cyclopentane
interferon gene
gene stimulator
sting modulators
based sting
Prior art date
Application number
MA052012A
Other languages
English (en)
Inventor
Andrew Fensome
Ketan S Gajiwala
Mehran Jalaie
Andreas Maderna
Indrawan James Mcalpine
Ryan Patman
Eugene Yuanjin Rui
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA52012A publication Critical patent/MA52012A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65744Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA052012A 2018-03-15 2019-03-12 Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane MA52012A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US201962809990P 2019-02-25 2019-02-25

Publications (1)

Publication Number Publication Date
MA52012A true MA52012A (fr) 2021-01-20

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052012A MA52012A (fr) 2018-03-15 2019-03-12 Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane

Country Status (24)

Country Link
US (4) US10538542B2 (fr)
EP (1) EP3765474B1 (fr)
JP (1) JP7266942B2 (fr)
KR (1) KR20200131878A (fr)
CN (1) CN111918871A (fr)
AU (1) AU2019234043A1 (fr)
BR (1) BR112020018593A2 (fr)
CA (1) CA3093631C (fr)
CL (1) CL2020002352A1 (fr)
CR (1) CR20200382A (fr)
DO (1) DOP2020000160A (fr)
EC (1) ECSP20057847A (fr)
ES (1) ES2923298T3 (fr)
IL (1) IL277278A (fr)
MA (1) MA52012A (fr)
MX (1) MX2020009587A (fr)
NI (1) NI202000058A (fr)
PE (1) PE20210412A1 (fr)
PH (1) PH12020551486A1 (fr)
RU (1) RU2020130048A (fr)
SG (1) SG11202008102VA (fr)
TW (1) TWI741268B (fr)
UY (1) UY38145A (fr)
WO (1) WO2019175776A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
GEP20237572B (en) * 2019-09-25 2023-11-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR20170015353A (ko) * 2014-06-04 2017-02-08 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Sting의 조절제로서 사이클릭 디­뉴클레오타이드
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
US20210230196A1 (en) 2021-07-29
WO2019175776A1 (fr) 2019-09-19
BR112020018593A2 (pt) 2020-12-29
PH12020551486A1 (en) 2021-08-23
RU2020130048A (ru) 2022-04-15
KR20200131878A (ko) 2020-11-24
US10538542B2 (en) 2020-01-21
CA3093631C (fr) 2023-01-24
ES2923298T3 (es) 2022-09-26
UY38145A (es) 2019-10-31
CL2020002352A1 (es) 2020-12-18
US10968242B2 (en) 2021-04-06
PE20210412A1 (es) 2021-03-04
IL277278A (en) 2020-10-29
NI202000058A (es) 2021-01-08
RU2020130048A3 (fr) 2022-04-15
US20200102334A1 (en) 2020-04-02
EP3765474B1 (fr) 2022-06-15
DOP2020000160A (es) 2020-09-30
EP3765474A1 (fr) 2021-01-20
CN111918871A (zh) 2020-11-10
SG11202008102VA (en) 2020-09-29
US20190284216A1 (en) 2019-09-19
MX2020009587A (es) 2020-10-05
ECSP20057847A (es) 2021-04-29
CA3093631A1 (fr) 2019-09-19
TW201945036A (zh) 2019-12-01
US20230382932A1 (en) 2023-11-30
JP2021518335A (ja) 2021-08-02
JP7266942B2 (ja) 2023-05-01
TWI741268B (zh) 2021-10-01
CR20200382A (es) 2020-12-10
AU2019234043A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MA52012A (fr) Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane
MA52709A (fr) Administration d'adn
MA54676A (fr) Vaccins à base d'arn contre le vrs
MA46245A (fr) Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron)
DK3399984T3 (da) Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf
IL276844A (en) Interferon gene stimulator agonists and their uses
CL2020000173S1 (es) Masajeador.
UA42295S (uk) Комп'ютер
MA46923A (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
DK3911354T3 (da) AVV-formidlet genterapi, der genskaber otoferlin-genet
MA54386A (fr) Modulateurs de trex1
MA53721A (fr) Modulateurs de la monoacylglycérol lipase
CA185676S (fr) Sac à dos
IL277921A (en) RNA new small operators
DK3737399T3 (da) Atf5-peptidvarianter og anvendelser deraf
MA49393A (fr) Poly(phosphoesters) destinés à l'administration d'acides nucléiques
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
MA53924A (fr) Modulateurs de l'expression d'apol1
EP3794410A4 (fr) Affichage électrophorétique piézoélectrique
MA55010A (fr) Système d'électrodes
MA54825A (fr) Modulateurs de gpr35
DK3833786T3 (da) Rekombinant nucleinsyrekonstrukt
MA51645A (fr) Modulateurs de l'expression de dnm2
WO2016123329A3 (fr) Marqueurs d'expression génique et traitement de la sclérose en plaques
DE112020002320A5 (de) Schmerzmedikament